Liquidia Announces Poster Presentations at the PHA 2024 International PH Conference and Scientific Sessions
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Liquidia Announces Poster Presentations at the PHA 2024 International PH Conference and Scientific Sessions
August 20, 2024 6:12 AM EDT
H.C. Wainwright analyst Andrew S. Fein lowered the price target on Liquidia Technologies (NASDAQ: LQDA) to $29.00 (from $32.00) while maintaining a Buy rating.
The analyst comments "Patent attorney's thoughts on competitor's patent exclusivity. From our conversations with a patent attorney, in terms of the patent exclusivity that was recently granted to Tyvasao, it is important to note that there are various types of exclusivity under the Hatch-Waxman Act. The New Chemical Entity (NCE) exclusivity ran out on Treprostinil five years after Remodulin was approved and only one NCE exclusivity is granted per... More
August 20, 2024 4:56 AM EDT
BofA Securities analyst Greg Harrison lowered the price target on Liquidia Technologies (NASDAQ: LQDA) to $23.00 (from $24.00) while maintaining a Buy rating.
The analyst comments "We update our LQDA PO to $23/shr (from $24) based on todays update the FDA will issue final Yutrepia... More
August 19, 2024 4:01 PM EDT
Jefferies analyst Kambiz Yazdi lowered the price target on Liquidia Technologies (NASDAQ: LQDA) to $17.00 (from $22.00) while maintaining a Buy rating.
The analyst comments "Tentative approval for Yutrepia in PAH and now PH-ILD was tempered by simultaneous grant of regulatory exclusivity for Tyvaso DPI until... More
August 19, 2024 11:15 AM EDT
BTIG analyst Julian Harrison lowered the price target on Liquidia Technologies (NASDAQ: LQDA) to $25.00 (from $29.00) while maintaining a Buy rating.
The analyst comments "Three-year New Clinical Investigation (NCI) Exclusivities are typically granted by the FDA soon after approval, making todays update unusual since Tyvaso DPI (UTHR, Neutral) has been approved since May 2022. 75% of... More
